Navigation Links
Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
Date:12/23/2009

mportant class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin for weight management, has completed a pivotal Phase 3 clinical trial program. Arena submitted lorcaserin's New Drug Application to the FDA in December 2009.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the development, therapeutic indication and use, tolerability, safety, and efficacy of MK-1903; the discontinuation of Arena's collaboration with Merck; future collaborative activities; the regulatory approval of lorcaserin; and Arena's focus, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, regulatory authorities may not accept Arena's NDA submission; regulatory authorities may not find data from Arena's clinical trials and studies sufficient for regulatory approval; the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; results of clinical trials or preclinical studies may not be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner or commercialize lorcaserin or other of its compounds or programs; Arena's ability to obtain additional funds; Arena's ability to obtain and defend its p
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medizone International Takes Aim at the Bioterrorism Countermeasures Arena
2. Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
3. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
4. Arena Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
5. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
6. Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
7. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
8. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
9. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
11. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Fla. , Aug. 26, 2014 ... under the symbol (NUUU) has two (2) wholly- ... Our two subsidiaries harness scientifically advanced technology to ... NUUU,s Renuell Int,l, Inc. is ... anti-aging skin care products that is made possible ...
(Date:8/26/2014)... 2014 Trovagene, Inc. (NASDAQ:  TROV) presented ... Moving Assays to the Clinic with an ... Cell Free Tumor DNA in Urine." In this ... Precision Cancer Monitoring (PCM) platform and results from ... detection of tumor DNA mutations from urine samples ...
(Date:8/26/2014)... -- Albany Molecular Research Inc. (NASDAQ: AMRI ... President and Chief Executive Officer at AMRI, will present ... September 8, 2014 at 8:45 a.m. ET. ... be accessed at AMRI,s Investor Relations web site at ... archived for 90 days following the live presentation. ...
(Date:8/26/2014)... Historically, drug development has faced a ... grow – high attrition rate, low productivity, patent ... regulatory hurdles and increasing concern about adverse ... the traditional business model of pharmaceutical companies is ... to find better ways to reduce operational costs ...
Breaking Biology Technology:Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4Transitioning from Bench into Clinical Phase, new webinar hosted by Xtalks 2
... - Educators and software developers will have the ... learning process at the first annual Games+Learning+Society conference ... conference is being held by Games And Professional Practice ... Learning (ADL) Co-Lab and a group of instructors at ...
... Marquette University and UGS, a provider ... the largest in-kind contribution ever presented to Marquette University, in ... a market value it says is more than $30.5 million. ... Jim Factor's Geometric Modeling Lab in the Department of Mathematics, ...
... Assembly on Thursday passed AB 499, a proposed ban on ... would outlaw the cloning of embryos both for reproductive purposes ... the making of a cloned embryo for the purpose of ... were to become law would go up to ten years ...
Cached Biology Technology:Education conference to draw together games researchers 2
(Date:8/25/2014)... fires began as a lightning strike on August 12, 2014. ... 20% contained. There are close to 2,000 personnel ... many small fires and a number of large ones. ... account for about 100 acres. An inversion layer settled ... on August 24, keeping fire activity moderate. As the inversion ...
(Date:8/25/2014)... Many Americans need extraordinary willpower to avoid becoming obese ... too much. For members of minority groups, maintaining a ... new research led by Luis Rivera, an experimental social ... common for minorities in the United States to endure ... inferior, and that these attitudes can prevent people from ...
(Date:8/25/2014)... 2014 Nearly 1 in 6 adults worldwide may ... disorder can cause serious complications. Auriculotherapy, a form ... the outer ear, may help in managing constipation. ... that evaluated the effectiveness of auriculotherapy in treating ... a Review article in The Journal of ...
Breaking Biology News(10 mins):Happy Camper and July Fire Complexes in California 2Racial and ethnic stereotypes may contribute to obesity among minorities 2
... its damaging effect on the environment and its illegal ... to adverse effects on human health, such as inflammation ... damage and possibly cancer. In a ... journal Environmental Research Letters, researchers took air ...
... pinpoint a small RNA that spurs cells to manufacture a ... Alzheimer,s disease (AD) or other types of neurodegeneration. The study ... of Cell Biology ( www.jcb.org ). Like ... in more than one version. Although scientists have identified numerous ...
... Nature a new molecular pathway used to suppress blood ... potential therapeutic value for fighting diseases of the retina and ... blood cells involved in the immune system, use this molecular ... in the same study researchers were able to reverse this ...
Cached Biology News:'E-waste pollution' a threat to human health, new research suggests 2Novel pathway regulating angiogenesis may fight retinal disease, cancers 2
... rapid analytical to medium scale affinity purification ... vectors. Sufficient reagents are provided for purification ... under native or denaturing conditions. Crude samples ... retains STag fusion proteins. After unbound proteins ...
High affinity antibody reacting with S-100 ab heterodimer. Could be used for Western blotting application and immunoassay....
... Ingredients (g/L):,Tryptone, 10 ,Yeast extract, 5 ... 0.3 ,Ferric ammonium citrate, 0.5 ,IPTG, ... water soluble, autoclavable chromogenic substrate for ... by -galactosidase generates a black insoluble ...
S-100 alpha/beta chain (8B10)...
Biology Products: